Piper Sandler analyst David Amsellem reiterated an Overweight rating and $37.00 price target on Revance Therapeutic (NASDAQ: RVNC) after conducted ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE